VincentTrien-VinhHoMD

Hematologic Oncology

Clinical Director, Allogeneic Hematopoietic Stem Cell Transplantation, Dana-Farber Cancer Institute. Associate Professor of Medicine, Harvard Medical School

Join to view full profile

Dr. Ho is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ho's full profile

Already have an account?

Office
44 Binney St
Boston, MA 02115
Phone+1 617-632-5938

Fax+1 617-632-5168

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1999 - 2002
Brigham and Women's HospitalResidency, Internal Medicine, 1997 - 1999
Brigham and Women's HospitalInternship, Internal Medicine, 1996 - 1997
Harvard Medical SchoolClass of 1996

Certifications & Licensure

RI State Medical License 2022 - 2026
MA State Medical License 2000 - 2025
NH State Medical License 2023 - 2025
American Board of Internal Medicine Medical Oncology

Clinical Trials

Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302) Start of enrollment: 2005 Sep 01
Completed
Phase 2
Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell Transplantation Start of enrollment: 2006 Jan 01
Completed
Phase 2
CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation Start of enrollment: 2005 Sep 01
Completed
Not Applicable
Effectiveness of Etanercept for Idiopathic Pneumonia Syndrome Following Stem Cell Transplantation (BMT CTN 0403) Start of enrollment: 2007 Aug 01
Completed
Phase 3
GM-CSF Vaccinations After Allogeneic Blood Stem Cell Transplantation in Patients With Advanced Myeloid Malignancies Start of enrollment: 2004 Jun 01
Completed
Not Applicable
Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation Start of enrollment: 2008 Nov 01
Completed
Phase 1
Collection and Banking of Leukemia Cells MDS/AML Start of enrollment: 2008 Oct 01
Completed
Not Applicable
Acute Graft-versus-Host Disease Treatment (BMT CTN 0802) Start of enrollment: 2010 Jan 01
Completed
Phase 3
Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies Start of enrollment: 2020 Jan 21
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Active infection at the time of CD34+ selected stem cell boost is associated with treatment failure and poor overall survival.
Roman M Shapiro, Haesook T Kim, Remy Dulery, Deborah Liney, Heather M Garrity
Blood Advances. 2024-09-10
Systematic identification of minor histocompatibility antigens predicts outcomes of allogeneic hematopoietic cell transplantation.
Nicoletta Cieri, Nidhi Hookeri, Kari Stromhaug, Liang Li, Julia Keating
Nature Biotechnology. 2024-08-21
Comparison of Older Related versus Younger Unrelated Donors for Older Recipients of Allogeneic Hematopoietic Cell Transplantation with Acute Myeloid Leukemia or Myelod...
Haesook T Kim, Vincent T Ho, Sarah Nikiforow, Corey Cutler, John Koreth
Transplantation and Cellular Therapy. 2024-07-01

Abstracts/Posters

Improved Outcomes with Cyclophosphamide/Total Body Irradiation 14 Gy Compared to Cyclophosphamide/Total Body Irradiation 12 Gy in Patients with Acute Lymphoblastic Leu...
Vincent T. Ho, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Na¥ve Patients with Relapsed or Refractory My...
Vincent T. Ho, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma
Vincent T. Ho, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase 1 Dose-Escalation Study of Adding Venetoclax to a Reduced Intensity Conditioning (RIC) Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for Patie...
Vincent T. Ho, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Single-Cell RNA-Seq Identifies Potentially Pathogenic B Cell Populations That Uniquely Circulate in Patients with Chronic Gvhd
Vincent T. Ho, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classic...
Vincent T. Ho, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Anti-CD6 Monoclonal Antibody Itolizumab Efficiently Inhibits T Cell Proliferation after in Vitro TCR Stimulation in the Setting of Acute Graft Versus Host Disease
Vincent T. Ho, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Distinct Evolutionary Patterns in Chronic Lymphocytic Leukemia (CLL) during Resistance to Graft-Versus-Leukemia (GvL)
Vincent T. Ho, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Graft Failure after Haploidentical Hematopoietic Stem Cell Transplantation
Vincent T. Ho, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B-Cell Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018